×
About 708 results

ALLMedicine™ Anaplastic Thyroid Carcinoma Center

Research & Reviews  270 results

Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeu...
https://doi.org/10.1007/978-3-030-83282-7_2 10.1016/S0092-8674(00)81683-9 10.1016/j.cell.2011.02.013 10.1111/j.1600-065X.1971.tb00461.x 10.1111/j.1600-065X.1976.tb00189.x 10.1038/nm.3909 10.1038/nri3920 10.1038/ni.3341 10.3389/fimmu.2015.00486 10.1158/0008-5472.CAN-07-0912 10.1016/j.ccr.2011.02.005 10.1016/j.ccell.2017.07.001 10.1038/s41577-019-0127-6 10.1016/j.cell.2008.09.016 10.20900/immunometab20190015 10.3390/cancers11060750 10.3389/fonc.2019.01143 10.1242/dmm.034272 10.1007/s00262-018-2195-z 10.3389/fimmu.2019.00925 10.1158/1078-0432.CCR-14-0291 10.1126/science.1198687 10.1038/sj.emboj.7600019 10.1016/j.intimp.2018.09.016 10.1038/nri3442 10.3892/ol.2017.5681 10.3389/fcell.2020.00766 10.3389/fimmu.2019.00147 10.1101/cshperspect.a006536 10.3390/ijms19051272 10.1186/s12943-017-0597-8 10.1016/j.semcancer.2019.06.003 10.1038/nrc.2016.73 10.1186/s12967-018-1536-1 10.3390/ijms19051532 10.3389/fimmu.2019.01835 10.1097/PPO.0000000000000118 10.1098/rsob.190297 10.3389/fonc.2020.00569 10.3389/fonc.2020.00722 10.1016/j.canlet.2019.07.010 10.1016/j.semcancer.2014.02.007 10.1038/s41423-020-0505-9 10.1016/j.immuni.2019.06.025 10.3390/ijms21155521 10.1016/j.cell.2004.07.011 10.1016/j.ccr.2013.03.004 10.1172/JCI39104 10.1038/nrm1835 10.1084/jem.20051848 10.1016/j.ccr.2012.04.024 10.1158/2326-6066.CIR-15-0241 10.1242/jcs.237453 10.1093/carcin/bgu060 10.3803/EnM.2013.28.3.192 10.1677/ERC-08-0036 10.1371/journal.pone.0022567 10.1002/path.1731 10.3892/mco.2013.170 10.1111/cen.12586 10.3892/ol.2019.9940 10.1073/pnas.0509182102 10.1097/MD.0000000000006472 10.3389/fonc.2019.01270 10.1038/s41416-019-0540-4 10.1158/10780432 10.1530/ERC-16-0421 10.1126/science.aar4060 10.1038/nrm3758 10.1007/s10911-010-9178-9 10.1074/jbc.M113.528026 10.1371/journal.pone.0036132 10.1038/srep09489 10.1016/j.stemcr.2014.03.008 10.1038/sj.bjc.6605530 10.1016/j.cell.2004.06.006 10.1016/j.tcb.2015.07.012 10.1101/gad.225334.113 10.1242/jcs.02552 10.1074/jbc.M005912200 10.1016/j.ccr.2009.03.016 10.1038/sj.onc.1210546 10.1016/j.canlet.2013.02.033 10.1186/s12902-019-0351-x 10.1158/0008-5472.CAN-05-2514 10.4049/JIMMUNOL.172.7.4100 10.1158/1078-0432.CCR-11-1595 10.1155/2013/857519 10.1186/s40425-018-0378-y 10.1097/CMR.0000000000000355 10.1210/jc.2018-01167 10.1016/j.immuni.2016.04.019 10.1016/j.prp.2019.04.002 10.3390/ijms20092198 10.1189/jlb.0809590 10.1172/JCI120966 10.1158/0008-5472.CAN-17-1653 10.1002/mc.22418 10.1158/1535-7163.MCT-19-0183
Advances in Experimental Medicine and Biology; Chakraborty S, Carnazza M et. al.

Dec 11th, 2021 - Thyroid cancer incidence is increasing at an alarming rate, almost tripling every decade. About 44,280 new cases of thyroid cancer (12,150 in men and 32,130 in women) are estimated to be diagnosed in 2021, with an estimated death toll of around 22...

Carcinoma Showing Thymus-like Differentiation (CASTLE) with Synchronous Papillary Thyro...
https://doi.org/10.1177/01455613211060167
Ear, Nose, & Throat Journal; Hsu YC, Hsueh C et. al.

Dec 7th, 2021 - Carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumor that accounts for 0.1%-0.15% of all thyroid cancers. More than half of the patients have tumor extension to adjacent organs, including the recurrent laryngeal nerve, ...

miR-381-3p attenuates doxorubicin resistance in human anaplastic thyroid carcinoma via ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576634
International Journal of Experimental Pathology; Zhang Y, Li K et. al.

Nov 2nd, 2021 - Abnormal microRNA (miR) expression has frequently been reported to be implicated in cancer-related drug resistance. Herein, we planned to investigate whether miR-381-3p contributes to doxorubicin (DOX) resistance in anaplastic thyroid carcinoma (A...

Thyroid crisis caused by metastatic thyroid cancer: an autopsy case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543858
BMC Endocrine Disorders; Takedani K, Notsu M et. al.

Oct 26th, 2021 - Thyroid crisis is a life-threatening condition in thyrotoxic patients. Although differentiated thyroid cancer is one of the causes of hyperthyroidism, reports on thyroid crisis caused by thyroid cancer are quite limited. Here, we describe a case o...

see more →

Guidelines  3 results

The revised clinical practice guidelines on the management of thyroid tumors by the Jap...
https://doi.org/10.1507/endocrj.EJ20-0025
Endocrine Journal; Ito Y, Onoda N et. al.

Apr 10th, 2020 - The Japan Associations of Endocrine Surgeons has developed the revised version of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines translated into English for the 35 clinical questions relevant to the ther...

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.
https://doi.org/10.6004/jnccn.2018.0089
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Nasr C et. al.

Dec 14th, 2018 - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summa...

Anaplastic Thyroid Carcinoma, Version 2.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986600
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Lydiatt WM et. al.

Sep 12th, 2015 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosage...

see more →

News  10 results

Next-Generation BRAF Inhibitor Plus Cobicistat Elicits Encouraging Activity in BRAF+ Refractory Solid Tumors
https://www.onclive.com/view/next-generation-braf-inhibitor-cobicistat-elicits-encouraging-activity-in-braf-refractory-solid-tumors

Oct 6th, 2021 - PLX8394, a next-generation BRAF inhibitor, in combination with cobicistat (Tybost) was found to demonstrate encouraging clinical activity with an acceptable safety profile in patients with BRAF-mutated, refractory solid tumors, according to result...

Sorafenib Improves PFS in Thyroid Cancer
https://www.onclive.com/view/sorafenib-improves-pfs-in-thyroid-cancer

Dec 4th, 2020 - A phase III trial of sorafenib (Nexavar) in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer met its primary endpoint of a statistically significant improvement in progression-free surv...

ASCO Names Progress in Treating Rare Cancers as Advance of the Year
https://www.onclive.com/view/asco-names-progress-in-treating-rare-cancers-as-advance-of-the-year

Dec 4th, 2020 - Monica M. Bertagnolli, MD, FACS, FASCO Due to major advancements made within the past year in the development of new therapies for patients with difficult-to-treat, rare cancers, ASCO has selected progress in treating rare cancers as its Advance ...

Targeted Treatment Tied to Longer Survival in Patients With Anaplastic Thyroid Cancer
https://www.staging.medscape.com/viewarticle/936044

Aug 21st, 2020 - NEW YORK (Reuters Health) - With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report. "Over the last 5 years, a greater understanding of the m...

Targeted Treatment Tied to Longer Survival in Patients With Anaplastic Thyroid Cancer
https://www.medscape.com/viewarticle/936044

Aug 21st, 2020 - NEW YORK (Reuters Health) - With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report. "Over the last 5 years, a greater understanding of the m...

see more →